Can a simple infusion shield kidney transplants from a dangerous virus?
NCT ID NCT07096453
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a drug called Cytogam (CMVIG) can prevent cytomegalovirus (CMV) infection in kidney transplant patients who are switching to a new immunosuppressant. The researchers will measure antibody levels in 30 adult patients over 8 weeks to see how the drug works in the body. The goal is to find a better way to protect transplant recipients from this common and serious infection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cytogam (CMVIG)
What this could lead to
If it works, this could point toward a way to prevent CMV infection in kidney transplant patients, reducing complications.
What could go wrong
This is a small early-phase pilot study with only 30 participants, so results may not apply broadly. It is testing antibody levels, not directly proving infection prevention.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CMV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact